First conditional marketing authorization approval in the European Union for hemophilia "A" gene therapy

VandenDriessche, ThierryPipe, Steven W.Pierce, Glenn F.Kaczmarek, Radoslaw2024-04-172024-04-172022VandenDriessche T, Pipe SW, Pierce GF, Kaczmarek R. First conditional marketing authorization approval in the European Union for hemophilia "A" gene therapy. Mol Ther. 2022;30(11):3335-3336. doi:10.1016/j.ymthe.2022.09.020https://hdl.handle.net/1805/40073en-USPublisher PolicyDrug approvalGenetic therapyHemophilia AFirst conditional marketing authorization approval in the European Union for hemophilia "A" gene therapyArticle